---
title: "Traws Pharma | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286553660.md"
datetime: "2026-05-15T11:07:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286553660.md)
  - [en](https://longbridge.com/en/news/286553660.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286553660.md)
---

# Traws Pharma | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.53.

EBIT: As of FY2026 Q1, the actual value is USD -6.946 M.

#### Cash and Cash Equivalents

As of March 31, 2026, Traws Pharma, Inc. reported cash and cash equivalents of $3.1 million, a decrease from $3.8 million as of December 31, 2025.

#### Revenue

Revenue for the quarter ended March 31, 2026, was $0.0 million, compared to $0.06 million for the comparable period in 2025.

#### Research and Development (R&D) Expense

R&D expense for Q1 2026 totaled $4.9 million, an increase of $2.4 million from $2.5 million in the comparable period of 2025, primarily due to increased expenses related to antiviral clinical trial milestones.

#### General and Administrative (G&A) Expense

G&A expense for Q1 2026 totaled $2.0 million, a decrease of $0.7 million from $2.8 million in the comparable period of 2025, mainly due to a decrease in professional and consulting fees.

#### Change in Fair Value of Warrant Liability

The change in fair value of warrant liability was an expense of $0.2 million for Q1 2026, contrasting with other income of $26.5 million for the comparable period in 2025.

#### Net Income (Loss)

Traws Pharma, Inc. reported a net loss of $7.1 million for Q1 2026, or a net loss of -$0.53 per basic and diluted common share, compared to a net income of $21.5 million, or $2.17 per basic and $2.09 per diluted common share, for Q1 2025.

#### Shares Outstanding

As of May 12, 2026, Traws Pharma, Inc. had 15,150,669 shares of common stock outstanding.

#### Operational Metrics and Business Highlights

On April 15, 2026, Traws Pharma, Inc. announced a private investment in public equity (PIPE) financing of up to $60 million, including $10 million in gross proceeds received at closing, with up to approximately $50 million of additional potential gross proceeds from milestone-based and three-year warrants. The company is progressing with the completion of a Phase 1 Bridging Study for Tivoxavir Marboxil (TXM) in Australia and plans a single-dose influenza virus challenge trial of TXM in the UK following MHRA approval. Traws Pharma, Inc. is also working to resolve a clinical hold placed by the FDA on the U.S. IND for TXM and plans to rapidly advance a clinical candidate for hantavirus treatment.

#### Outlook / Guidance

The recently announced private financing is estimated to provide sufficient resources to fund Traws Pharma, Inc.’s operations into Q1 2027, covering the completion of a human challenge trial for TXM. The company plans to initiate a human challenge trial for TXM as a once-monthly prophylactic agent against seasonal influenza in Q2 2026 and aims to resolve the FDA clinical hold and initiate global studies by year-end. Additionally, Traws Pharma, Inc. intends to move rapidly to advance a clinical candidate for hantavirus treatment.

### Related Stocks

- [TRAW.US](https://longbridge.com/en/quote/TRAW.US.md)

## Related News & Research

- [Traws Pharma, Inc. 1Q 2026: Revenue $0 EPS $(0.53) — 10-Q Summary](https://longbridge.com/en/news/286555967.md)
- [TDK publishes 2026 annual report for fiscal year ended March 31, 2026](https://longbridge.com/en/news/287131408.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md)